Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928600 | 0.85 | SIGMAR1 (0.47) | ALDH1A1SIGMAR1 | |
| SCHEMBL6774733 | 0.85 | SIGMAR1 (0.47) | ALDH1A1SIGMAR1 | |
| SCHEMBL7003184 | 0.77 | DRD2 (0.51) | ALDH1A1POLBDRD2DRD4DRD3 | |
| SCHEMBL6153609 | 0.72 | DRD2 (0.50) | ALDH1A1POLBDRD2DRD4DRD3 | |
| SCHEMBL13986863 | 0.72 | SIGMAR1 (0.36) | ALDH1A1SIGMAR1 | |
| SCHEMBL5971566 | 0.70 | DRD2 (0.54) | DRD2DRD4DRD3SIGMAR1SLC6A2 | |
| SCHEMBL10816114 | 0.67 | OPRK1 (0.49) | ALDH1A1POLBDRD2DRD4DRD3 | |
| SCHEMBL6153361 | 0.66 | DRD2 (0.54) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL30833222 | 0.66 | DRD2 (0.51) | DRD2DRD4DRD3SLC6A2LTA4H | |
| SCHEMBL3880873 | 0.66 | DRD2 (0.51) | DRD2DRD4DRD3SLC6A2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326867-A2 | BRIDGED PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20020119961-A1 | Bridged piperazine derivatives | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002032901-A2 | BRIDGED PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119961-A1 | Bridged piperazine derivatives | MYD88, IL4, ARG1 | ALDH1A1 772/4885POLB 3658/4885DRD2 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.